iCAD (ICAD) Competitors $2.14 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.13 -0.01 (-0.47%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ICAD vs. NVRO, ELMD, PROF, LAKE, INGN, DRTS, AVR, BWAY, SKIN, and OBIOShould you be buying iCAD stock or one of its competitors? The main competitors of iCAD include Nevro (NVRO), Electromed (ELMD), Profound Medical (PROF), Lakeland Industries (LAKE), Inogen (INGN), Alpha Tau Medical (DRTS), Anteris Technologies Global (AVR), BrainsWay (BWAY), Beauty Health (SKIN), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. iCAD vs. Nevro Electromed Profound Medical Lakeland Industries Inogen Alpha Tau Medical Anteris Technologies Global BrainsWay Beauty Health Orchestra BioMed Nevro (NYSE:NVRO) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, community ranking, profitability, analyst recommendations, valuation and dividends. Do insiders and institutionals hold more shares of NVRO or ICAD? 95.5% of Nevro shares are owned by institutional investors. Comparatively, 24.6% of iCAD shares are owned by institutional investors. 3.2% of Nevro shares are owned by insiders. Comparatively, 10.3% of iCAD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in NVRO or ICAD? Nevro received 276 more outperform votes than iCAD when rated by MarketBeat users. Likewise, 62.61% of users gave Nevro an outperform vote while only 61.29% of users gave iCAD an outperform vote. CompanyUnderperformOutperformNevroOutperform Votes50462.61% Underperform Votes30137.39% iCADOutperform Votes22861.29% Underperform Votes14438.71% Does the media favor NVRO or ICAD? In the previous week, Nevro and Nevro both had 4 articles in the media. iCAD's average media sentiment score of 0.18 beat Nevro's score of -0.27 indicating that iCAD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nevro 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iCAD 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate NVRO or ICAD? Nevro currently has a consensus target price of $6.43, suggesting a potential upside of 9.92%. Given Nevro's stronger consensus rating and higher probable upside, research analysts plainly believe Nevro is more favorable than iCAD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nevro 2 Sell rating(s) 10 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.92iCAD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, NVRO or ICAD? iCAD has lower revenue, but higher earnings than Nevro. iCAD is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNevro$408.52M0.55-$92.21M-$3.05-1.92iCAD$19.61M2.90-$4.85M-$0.21-10.19 Is NVRO or ICAD more profitable? Nevro has a net margin of -16.54% compared to iCAD's net margin of -17.81%. iCAD's return on equity of -15.65% beat Nevro's return on equity.Company Net Margins Return on Equity Return on Assets Nevro-16.54% -23.52% -10.83% iCAD -17.81%-15.65%-12.52% Which has more risk & volatility, NVRO or ICAD? Nevro has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. SummaryNevro beats iCAD on 10 of the 17 factors compared between the two stocks. Remove Ads Get iCAD News Delivered to You Automatically Sign up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICAD vs. The Competition Export to ExcelMetriciCADSurgical & medical instruments IndustryComputer SectorNASDAQ ExchangeMarket Cap$56.00M$4.37B$23.36B$8.00BDividend YieldN/A32.64%2.83%4.01%P/E Ratio-16.2328.7242.6618.89Price / Sales2.8650.251,979.8592.98Price / CashN/A51.0834.6134.64Price / Book1.666.106.214.30Net Income-$4.85M$67.64M$735.89M$247.06M7 Day Performance-5.38%-3.67%-0.36%-0.62%1 Month Performance-12.45%-2.08%49,592.15%-4.26%1 Year Performance31.06%10.75%52,075.94%0.61% iCAD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICADiCAD0.5012 of 5 stars$2.14flatN/A+33.8%$56.80M$19.61M-16.46140Analyst UpgradeNVRONevro0.8922 of 5 stars$5.79+0.3%$6.43+11.1%-59.5%$221.98M$408.52M-3.061,215ELMDElectromed1.0968 of 5 stars$24.45-1.1%$38.00+55.4%+45.5%$209.22M$59.63M32.60160Analyst DowngradePROFProfound Medical2.1784 of 5 stars$6.81flat$14.25+109.3%-25.2%$204.57M$10.68M-5.08150LAKELakeland Industries4.7978 of 5 stars$21.09+12.4%$28.33+34.3%+25.4%$200.33M$151.82M-234.331,800Analyst UpgradeNews CoverageINGNInogen2.9402 of 5 stars$7.37+0.3%$7.00-5.0%-10.4%$195.53M$335.71M-3.281,030DRTSAlpha Tau Medical1.8641 of 5 stars$2.70+3.4%$8.00+196.3%-9.8%$188.80MN/A-6.2880Short Interest ↑AVRAnteris Technologies GlobalN/A$5.12-1.2%$16.50+222.3%N/A$184.44M$2.71M0.00138News CoverageHigh Trading VolumeBWAYBrainsWay2.7374 of 5 stars$9.77-1.4%$13.17+34.8%+83.0%$183.94M$41.02M97.71120Short Interest ↑Gap DownSKINBeauty Health1.9671 of 5 stars$1.41+7.6%$2.50+77.3%-70.0%$175.01M$334.29M-3.361,030OBIOOrchestra BioMed1.75 of 5 stars$4.57+1.3%$15.40+237.0%-13.3%$173.72M$2.65M-2.844Gap Up Remove Ads Related Companies and Tools Related Companies Nevro Alternatives Electromed Alternatives Profound Medical Alternatives Lakeland Industries Alternatives Inogen Alternatives Alpha Tau Medical Alternatives Anteris Technologies Global Alternatives BrainsWay Alternatives Beauty Health Alternatives Orchestra BioMed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ICAD) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iCAD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iCAD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
